Junshi Biosciences has invested in the University of Birmingham-founded cancer immunotherapy developer, building on a research collaboration deal.
Revitope Oncology, a US-based cancer therapeutics spinout of University of Birmingham, yesterday obtained $10m in equity funding from biopharmaceutical firm Junshi Biosciences.
Junshi will take a 9.99% stake having already entered an up to $800m collaboration and licensing agreement with the spinout in June 2020, when Junshi first made a conditional commitment to invest $10m.
Founded in 2014, Revitope Oncology has created a protein engineering platform that allows antibodies to split into two halves once in the body…
